A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Anlotinib (Primary) ; Dacarbazine
- Indications Alveolar soft part sarcoma; Leiomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Acronyms APROMISS
- Sponsors Advenchen Laboratories
- 02 Sep 2017 Planned number of patients changed from 216 to 219.
- 15 Jun 2017 Status changed from not yet recruiting to recruiting.
- 26 Jan 2017 Planned End Date changed from 1 Jun 2021 to 1 Aug 2021.